Evidence map›Paper›PMID 27423310›Full record

ArticleOphthalmology2016

Orbital Angiogenesis and Lymphangiogenesis in Thyroid Eye Disease: An Analysis of Vascular Growth Factors with Clinical Correlation.

Lindsay L Wong, Nahyoung Grace Lee, Dhanesh Amarnani, Catherine J Choi, Diane R Bielenberg, Suzanne K Freitag, Patricia A D'Amore, Leo A Kim

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04311606 (Anti-VEGF Therapy for Acute Thyroid Eye Disease), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04311606 phase2completednot on this mapstarted 2020, after this paper: background citation

Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study)

TypeinterventionalSponsorMassachusetts Eye and Ear InfirmaryRan2020 to 2024Enrolled11ConditionsThyroid Eye DiseaseArmsSub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Transcriptomic and Neuroimaging Decoding of Brain-Immune Crosstalk in Thyroid Eye Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022
    Article
  14. Future Projections in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Lindsay L WongSchepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Nahyoung Grace LeeDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Dhanesh AmarnaniSchepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Catherine J ChoiDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Diane R BielenbergDepartment of Surgery, Harvard Medical School, Children's Hospital of Boston, Boston, Massachusetts.
Suzanne K FreitagDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Patricia A D'AmoreSchepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Leo A KimSchepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. Electronic address: Leo_Kim@meei.harvard.edu.
Smith-Kettlewell Eye Research Institute · USHarvard University · USMassachusetts Eye and Ear Infirmary · USBoston Children's Hospital · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
THE ROLE OF MICROVASCULAR CELLS IN NEOVASCULARIZATIONR01EY005318 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI D'AMORE, PATRICIA ANN · 1985 to 2015
$6.4M
Vasculogenesis in Thyroid Eye DiseaseR21EY027061 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI KIM, LEO A · 2016 to 2017
$542k
NEI NIH HHS K12 EY016335NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY005318NEI NIH HHS R21 EY027061
6 · The paper itself

Abstract

purposeThe human orbit is an environment that is vulnerable to inflammation and edema in the setting of autoimmune thyroid disease. Our study investigated the tenet that orbital adipose tissue lacks lymphatic vessels and analyzed the clinicopathologic differences between patients with acute and chronic thyroid eye disease (TED). The underlying molecular mediators of blood and lymphatic vessel formation within the orbital fat also were evaluated.

designRetrospective cohort study.

participantsThe study included fat specimens from 26 orbits of 15 patients with TED undergoing orbital decompression. Orbital fat specimens from patients without TED as well as cadaveric orbital fat served as controls.

methodsTissue specimens were processed as formalin-fixed, paraffin-embedded sections or frozen cryosections for immunohistochemistry. Total RNA was extracted and analyzed via quantitative (real-time) reverse-transcription polymerase chain reaction. Clinicopathologic correlation was made by determining the clinical activity score (CAS) of each patient with TED.

main outcome measuresSamples were examined for vascular and lymphatic markers including podoplanin, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and cluster of differentiation 31 (CD31) by immunohistochemistry, as well as for mRNA levels of vascular endothelial growth factor (VEGF), VEGF receptors, semaphorin 3F, neuropilin 1, neuropilin 2, podoplanin, and LYVE-1 by quantitative (real-time) reverse-transcription polymerase chain reaction.

resultsClinicopathologic correlation revealed increased staining of CD31-positive blood vessels in patients with acute TED with a CAS more than 4, as well as rare staining of podoplanin-positive lymphatic vessels within acutely inflamed orbital fat tissue. Additionally, quantitative (real-time) reverse-transcription polymerase chain reaction analysis demonstrated increased expression of VEGF receptor (VEGFR) 2 as well as VEGF signaling molecules VEGF-A, VEGF-C, and VEGF-D.

conclusionsIn acute TED, compared with chronic TED and control orbital fat, there is increased blood vessel density, suggesting neovascularization and rare lymphatic vessels suggestive of limited lymphangiogenesis. This proangiogenic and prolymphangiogenic microenvironment is likely the result of the increased expression of VEGFR-2, VEGF-A, VEGF-C, and VEGF-D. These findings imply that orbital edema in acute TED may be mediated, in part, by both the formation of new, immature blood vessels and the formation of lymphatic capillaries that are functionally incapable of draining interstitial fluid.

Indexed as

Adipose TissueAdultAgedBiomarkersCase-Control StudiesFemaleGraves OphthalmopathyHumansImmunohistochemistryIntercellular Signaling Peptides and ProteinsLymphangiogenesisLymphatic VesselsMaleMiddle AgedNeovascularization, PathologicReal-Time Polymerase Chain ReactionBiomarkersIntercellular Signaling Peptides and ProteinsReceptors, Vascular Endothelial Growth FactorRNA, MessengerVascular Endothelial Growth Factors

Identifiers

PMID27423310
PMCPMC5536972
OpenAlexW2461088837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.